Amplia Therapeutics (ASX:ATX) PS Ratio: (As of Jul. 02, 2026)


ASX:ATX Amplia Therapeutics Ltd ASX:ATX
36 GF Score
Price A$0.15
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Amplia Therapeutics's share price is A$0.15. Amplia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.00. Hence, Amplia Therapeutics's PS Ratio for today is .

The historical rank and industry rank for Amplia Therapeutics's PS Ratio or its related term are showing as below:

During the past 13 years, Amplia Therapeutics's highest PS Ratio was 13862.46. The lowest was 43.59. And the median was 130.00.

ASX:ATX's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.46
* Ranked among companies with meaningful PS Ratio only.

Amplia Therapeutics's Revenue per Sharefor the six months ended in Mar. 2026 was A$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.00.

Back to Basics: PS Ratio


Amplia Therapeutics  (ASX:ATX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Amplia Therapeutics PS Ratio Related Terms


Amplia Therapeutics PS Ratio Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics PS Ratio Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:ATX vs VRTX, REGN, ALNY: PS Ratio Comparison

For the Biotechnology subindustry, Amplia Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amplia Therapeutics PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's PS Ratio falls into.


ASX:ATX
36GF Score
Amplia Therapeutics Ltd ASX:ATX
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Amplia Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.15/0
=

Amplia Therapeutics's Share Price of today is A$0.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Amplia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
36GF Score

Get the complete analysis for ASX:ATX

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price